Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
Award amount
$414,721Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTEGRAL MOLECULAR INC
- Proposal award date
- 2018-09-01
- Contract end date
- 2020-05-31
- UEI
- DY9KSWE8EJB8
- Solicitation number
- PAS17-064
- Topic code
- NIA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS
- High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA
- Specificity Screening Drug Development Tool for Biotherapeutic Safety
- Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
- Reagents for Immunologic Analysis of Under-represented Mammalian Models
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
48 SBIR/STTR records share this UEI (2002–2025). Reported award amounts total $32,839,788. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services